Inhibitory effects of TTP sera on binding of anti-platelet glycoprotein IIb-IIIa monoclonal antibodies to human vascular endothelial cells.
The binding of anti-human platelet glycoprotein (GP) IIbIIIa monoclonal antibodies to human umbilical vein endothelial cells (HUVE) was studied. Scatchard analysis using 125I-anti-platelet GPIIb-IIIa monoclonal antibody showed that the maximum binding capacity (B max) was 8 X 10(4)/cell and Kd was 40.2 nM. The binding rate of 125I-anti-platelet GPIIbIIIa monoclonal antibodies to HUVE treated with TTP sera was 11.6 +/- 2.8%, compared with the 24.0 +/- 7.5% observed for HUVE treated with normal sera. These findings showed that there are GPIIb-IIIa on HUVE and that TTP sera may contain anti-platelet GPIIbIIIa antibodies.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D001666:Binding Sites, Antibody; D004727:Endothelium / Q000166:cytology*; D005260:Female; D006801:Humans; D010980:Platelet Membrane Glycoproteins / Q000276:immunology*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood*; D014471:Umbilical Veins / Q000166:cytology
D000911:Antibodies, Monoclonal; D010980:Platelet Membrane Glycoproteins